Illumina (NASDAQ:ILMN) Stock: Insider Keith Meister Sells 118,567 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 118,567 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $220.55, for a total value of $26,149,951.85. Following the sale, the director directly owned 370,350 shares of the company’s stock, valued at $81,680,692.50. This represents a 24.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Illumina Stock Performance

ILMN traded down $3.38 during midday trading on Thursday, reaching $209.55. The company had a trading volume of 1,726,386 shares, compared to its average volume of 2,186,053. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average of $249.39 and a two-hundred day moving average of $179.08. The company has a market cap of $31.68 billion, a P/E ratio of 36.07, a P/E/G ratio of 2.92 and a beta of 1.46. Illumina, Inc. has a 1 year low of $112.65 and a 1 year high of $309.35.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the company earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, equities research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fiduciary Financial Advisors purchased a new position in Illumina during the second quarter valued at $26,000. MCF Advisors LLC lifted its stake in Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. purchased a new stake in Illumina in the 3rd quarter worth $31,000. Keating Financial Advisory Services Inc. purchased a new stake in Illumina in the 2nd quarter worth $32,000. Finally, Rakuten Securities Inc. bought a new position in shares of Illumina during the 2nd quarter valued at about $33,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Argus raised their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Evercore reissued an “underperform” rating on shares of Illumina in a report on Friday, October 30th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Stifel Nicolaus increased their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $244.24.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.